- Home
- ANTX vs PMN Comparison
ANTX vs PMN Comparison
Compare ANTX & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- PMN
- Stock Information
- Founded
- ANTX 2017
- PMN 2004
- Country
- ANTX United States
- PMN Canada
- Employees
- ANTX N/A
- PMN N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- PMN Pharmaceuticals and Biotechnology
- Sector
- ANTX Health Care
- PMN Health Care
- Exchange
- ANTX Nasdaq
- PMN Nasdaq
- Market Cap
- ANTX 40.0M
- PMN 32.3M
- IPO Year
- ANTX 2022
- PMN N/A
- Fundamental
- Price
- ANTX $1.44
- PMN $0.90
- Analyst Decision
- ANTX Hold
- PMN
- Analyst Count
- ANTX 5
- PMN 0
- Target Price
- ANTX $3.50
- PMN N/A
- AVG Volume (30 Days)
- ANTX 298.6K
- PMN 78.7K
- Earning Date
- ANTX 11-13-2024
- PMN 01-07-2025
- Dividend Yield
- ANTX N/A
- PMN N/A
- EPS Growth
- ANTX N/A
- PMN N/A
- EPS
- ANTX N/A
- PMN N/A
- Revenue
- ANTX N/A
- PMN N/A
- Revenue This Year
- ANTX N/A
- PMN N/A
- Revenue Next Year
- ANTX N/A
- PMN N/A
- P/E Ratio
- ANTX N/A
- PMN N/A
- Revenue Growth
- ANTX N/A
- PMN N/A
- 52 Week Low
- ANTX $0.87
- PMN $0.87
- 52 Week High
- ANTX $22.22
- PMN $3.10
- Technical
- Relative Strength Index (RSI)
- ANTX 56.85
- PMN 42.97
- Support Level
- ANTX $1.23
- PMN $0.89
- Resistance Level
- ANTX $1.43
- PMN $0.95
- Average True Range (ATR)
- ANTX 0.09
- PMN 0.05
- MACD
- ANTX -0.01
- PMN 0.00
- Stochastic Oscillator
- ANTX 58.33
- PMN 21.43
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.